Emma Simonsen

Emma Simonsen

Auto-generated profile, based on publicly available information

Emma Simonsen

Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Odense, Denmark

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 March 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
ESEmma Simonsen
Emma Simonsen
LLLars Christian Lund
Lars Christian Lund
MEMartin Thomsen Ernst
Martin Thomsen Ernst
VHVidar Hjellvik
Vidar Hjellvik
LHLaszlo Hegedüs
Laszlo Hegedüs
APAnton Pottegård
Anton Pottegård
Aims: To investigate the putative association between semaglutide and non‐arteritic anterior ischaemic optic neuropathy (NAION). Materials and Methods: Data from national health registries in Denmark (2018–2024) and Norway (2018–2022) were used to compare NAION risk in individuals with type 2 diabetes initiating semaglutide versus sodium‐glucose co‐transporter 2 inhibitors (SGLT‐2is). A supplementary self‐controlled analysis examined NAION risk among all semaglutide users. National estimates were pooled using a fixed‐effects model. Results: We identified 44 517 users of semaglutide for the management of type 2 diabetes in Denmark and 16 860 in Norway, with a total of 32 NAION events observed. The unadjusted incidence rate of NAION was 2.19/10 000 person‐years among Danish semaglutide initiators, compared to 1.18 among SGLT‐2i initiators. In Norway, the corresponding rates were 2.90 and 0.92, respectively. After adjustment, the pooled hazard ratio (HR) was 2.81 (95% confidence interval [CI] 1.67–4.75), and the incidence rate difference (IRD) was +1.41 (95% CI +0.53 to +2.29) per 10 000 person‐years. Estimates were consistent across both countries but higher and less precise in Norway (HR 7.25; 95% CI 2.34–22.4) compared to Denmark (HR 2.17; 95% CI 1.20–3.92). Results remained consistent across sensitivity and supplementary analyses, with a stronger association observed in a post hoc per‐protocol analysis (HR 6.35; 95% CI 2.88–14.0). In the supplementary self‐controlled study, symmetry ratios (SRs) for NAION were 1.14 (95% CI 0.55–2.36) in Denmark and 2.67 (95% CI 0.91–8.99) in Norway. Conclusions: The use of semaglutide for managing type 2 diabetes is associated with an increased risk of NAION compared with the use of SGLT‐2is. However, the absolute risk remains low.

11 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
ESEmma Simonsen
Emma Simonsen
LLLars Christian Lund
Lars Christian Lund
MEMartin Thomsen Ernst
Martin Thomsen Ernst
VHVidar Hjellvik
Vidar Hjellvik
LHLaszlo Hegedüs
Laszlo Hegedüs
APAnton Pottegård
Anton Pottegård
Importance Recent findings have raised concerns about an association between semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), and non-arteritic anterior ischemic optic neuropathy (NAION). Objective To further investigate the putative association between semaglutide use and NAION. Design Bi-national active comparator new-user cohort study with propensity score weighing to adjust for confounding, fixed-effect meta-analysis, and a supplementary self-controlled analysis (symmetry analysis). Setting Data were obtained from national health registries in Denmark and Norway, including prescription registries, patient registries, and civil registration systems. Participants New users of semaglutide and sodium-glucose co-transporter 2 inhibitors (SGLT-2is) during 2018-2022 (Norway) and 2018-2024 (Denmark). Exposures Initiation of semaglutide and SGLT-2is for the management of type 2 diabetes was assessed in the main analysis. In the self-controlled design, exposure to semaglutide, regardless of indication, was investigated. Main Outcomes and Measures Incidence rates of NAION among semaglutide and SGLT-2is users, along with hazard ratios (HRs) and incidence rate differences (IRDs) with robust 95% confidence intervals. Estimates from Denmark and Norway were pooled using a fixed-effects model (inverse variance weighting). The supplementary self-controlled study returned sequence symmetry ratios (SRs). Results We identified 44,517 eligible users of semaglutide for the management of type 2 diabetes in Denmark and 16,860 in Norway. In total, we observed 32 NAION events among semaglutide users (24 in Denmark and 8 in Norway). This yielded an unadjusted incidence rate of NAION of 2.19/10,000 person-years among Danish semaglutide initiators, compared to 1.18 among SGLT-2i initiators. The corresponding unadjusted incidence rates in Norway were 2.90 and 0.92. After adjustment, we obtained a pooled HR of 2.81 (95% CI 1.67 to 4.75) and IRD of +1.41 (95% CI +0.53 to +2.29). Estimates were compatible in the individual countries, although with higher and less precise estimates in Norway (HR 7.25; 95% CI 2.34 to 22.4) compared to Denmark (HR 2.17; 95% CI 1.20 to 3.92). Results were consistent across sensitivity and supplementary analysis, with a notably stronger association observed in a post hoc per-protocol analysis (HR 6.35; 95% CI 2.88 to 14.0). In the supplementary self-controlled study, SRs for NAION were 1.14 (95% CI 0.55 to 2.36) in Denmark and 2.67 (95% CI 0.91 to 8.99) in Norway. Conclusions and Relevance Our findings show an association between use of semaglutide for type 2 diabetes and risk of NAION. However, the absolute risk remains low. Question Is there an association between semaglutide use and risk of non-arteritic anterior ischemic optic neuropathy (NAION)? Findings In this cohort study conducted in Denmark and Norway, use of semaglutide was associated with an increased risk of NAION; the pooled hazard ratio was 2.81 (95% confidence interval (CI) 1.67 to 4.75) and the incidence rate difference (absolute risk increase) was +1.41 (95% CI +0.53 to +2.29) NAION events per 10,000 person-years. The finding was consistent across sensitivity and supplementary analysis. Meaning Our study confirms that use of semaglutide is associated to an increased risk of NAION, but also that the excess absolute risk is low.

29 August 2025 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
ESEmma Simonsen
Emma Simonsen
SWShirley V. Wang
Shirley V. Wang
HKHelene Kildegaard
Helene Kildegaard
APAnton Pottegård
Anton Pottegård
Background: Preregistration of study protocols in a public repository promotes transparency and reproducibility in pharmacoepidemiological research. Despite its clear benefits, preregistration remains underutilized. Purpose: Here, we discuss the advantages of preregistration, explore barriers to its implementation, and highlight existing repositories for preregistering real‐world evidence study protocols. A relatively new option is the Real‐World Evidence Registry within the Open Science Framework (OSF), which we briefly introduce.

26 May 2026 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
LLLars Christian Lund
Lars Christian Lund
ESEmma Simonsen
Emma Simonsen
APAnton Pottegård
Anton Pottegård
To perform active safety monitoring of newer glucose-lowering therapies. Using Danish nationwide registries, we conducted an active comparator new user cohort study comparing adverse events among initiators of sodium-glucose co-transporter 2 inhibitors (SGLT2is), glucagon-like peptide 1 receptor agonists (GLP1-RAs), and dipeptidyl peptidase 4 inhibitors (DPP4is). We identified 49 365 SGLT2i, 33 018 GLP1-RA, and 50 531 DPP4i initiators. Of 43 associations identified, we disregarded obesity-related signals (N = 2) and observed beneficial effects (N = 7). SGLT2i initiators had higher risks of phimosis (vs. GLP1-RA: hazard ratio [HR] 1.69, 95% compatibility intervals [CI] 1.42-2.02; vs. DPP4i: HR 2.19, 95% CI 1.84-2.59) and secondary polycythaemia (vs. GLP1-RA: HR 2.67, 95% CI 1.62-4.38; vs. DPP4i: HR 1.63, 95% CI 1.14-2.32). DPP4i initiators had increased risk of bacterial intestinal infections (vs. SGLT2i: HR 1.56, 95% CI 1.18-2.08; vs. GLP1-RA: HR 2.08, 95% CI 1.49-2.94) and anaemia (vs. SGLT2i: HR 2.00, 95% CI 1.22-3.23; vs. GLP1-RA: HR 1.92, 95% CI 1.18-3.23). GLP1-RA initiators had a near-immediate elevated risk of uterine cancer (vs. SGLT2i: HR 1.82, 95% CI 1.20-2.78; vs. DPP4i: HR 1.94, 95% CI 1.19-3.16). While some signals likely reflect residual confounding, several signals - particularly those related to infections and cancer - warrant further investigation.

27 March 2025 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Open access
ESEmma Simonsen
Emma Simonsen
CMChristina Mortensen
Christina Mortensen
CRCathrine Lundgaard Riis
Cathrine Lundgaard Riis
KSKarina Dahl Steffensen
Karina Dahl Steffensen
MOMorten Olesen
Morten Olesen
APAnton Pottegård
Anton Pottegård
Recent evidence suggests that atorvastatin exacerbates paclitaxel neurotoxicity via P‐glycoprotein inhibition. We used a translational approach to investigate if atorvastatin or simvastatin exacerbates (i) paclitaxel neurotoxicity in human sensory neurons and (ii) paclitaxel‐induced peripheral neuropathy (PIPN) in cancer patients. Paclitaxel neurotoxicity was assessed by quantifying neuronal networks of human induced pluripotent stem cell‐derived sensory neurons (iPSC‐SNs) with and without atorvastatin or simvastatin exposure. We estimated the odds ratio (OR) of early paclitaxel discontinuation due to PIPN in a nationwide cohort of paclitaxel‐treated women (2014–2018), comparing atorvastatin users to simvastatin users and nonusers of statins. Only the highest concentration of atorvastatin (100 nM) significantly exacerbated paclitaxel neurotoxicity in iPSC‐SNs ( p < 0.05). Among 576 paclitaxel‐treated women, atorvastatin use was not significantly associated with early paclitaxel discontinuation due to PIPN, with adjusted ORs of 0.80 [95% confidence interval (CI) 0.34–1.88] compared with simvastatin, and 1.24 [95% CI 0.44–3.53] compared with nonuse. Supplementary analyses showed varying but statistically nonsignificant results. Our in vitro findings suggest that atorvastatin, not simvastatin, significantly worsens paclitaxel neurotoxicity. However, no link was found between atorvastatin use and early paclitaxel discontinuation due to PIPN. Larger, well‐designed studies are required to clarify the discrepancy between in vitro and clinical data and the inconsistencies with previous clinical evidence.

25 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ESEmma Simonsen
Emma Simonsen
MEMartin Thomsen Ernst
Martin Thomsen Ernst
DCDiana Hedevang Christensen
Diana Hedevang Christensen
HKHelene Kildegaard
Helene Kildegaard
Jens SøndergaardJens Søndergaard
Jens Søndergaard
APAnton Pottegård
Anton Pottegård
Objectives: To evaluate the impact of reimbursement restrictions for glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes, introduced in Denmark in November 2024, on injectable semaglutide (Ozempic®) utilization patterns and subsequent HbA1c changes among discontinuers. Design: Nationwide registry-based cohort study. Setting: Denmark. Participants: Adults treated with injectable semaglutide for diabetes (January 2018 to December 2025). Main outcome measures: We described temporal patterns in injectable semaglutide use before and after the policy change. Among semaglutide continuers after the policy change, we assessed whether continuation met a key criterion in the new policy: non-feasibility of sodium-glucose cotransporter 2 inhibitor use and high cardiovascular risk. We characterized semaglutide discontinuers around the policy implementation (March 2024 to November 2024) and subsequent treatment switches. Among discontinuers, we evaluated HbA1c changes and performed interrupted time series (ITS) analyses. Results: Following the policy change, use of injectable semaglutide declined modestly before subsequently increasing. Among 61,120 individuals classified as semaglutide continuers, 27,143 (44%) were already using an SGLT2i. Of the remaining 33,977 (56%), only 1,862 (5.5%) met a key reimbursement criterion (i.e., non-feasibility of SGLT2i use and high cardiovascular risk). Among 79,305 individuals with a semaglutide fill between March 2024 and November 2024, 22,096 (28%) were classified as discontinuers. Within six months, ∼40% of discontinuers switched to other glucose-lowering therapies, most commonly SGLT2is (24%). 37% of discontinuers later reinitiated semaglutide. Among individuals with an on-treatment HbA1c measurement (within 12 months before their last semaglutide fill) and an off-treatment HbA1c measurement (6-12 months after their last semaglutide fill) (n=13,017), mean HbA1c increased from 49 to 57 mmol/mol (mean change +7.4 mmol/mol, 95% CI 7.2-7.6). ITS analysis showed that HbA1c increased by 5.9 mmol/mol (95% CI 5.1-6.7) at six months post-discontinuation, which attenuated to 3.1 mmol/mol (95% CI 2.2-4.1) at 12 months; raw monthly means (not included in the ITS model) suggested this persisted through 18 months. Conclusions: Following the policy change, population-level use of injectable semaglutide declined modestly before increasing again. Most discontinuers did not initiate another glucose-lowering therapy and experienced an increase in HbA1c that did not fully return to pre-discontinuation levels during follow-up. What is already known on this topic: The rapid uptake and high costs of GLP-1 receptor agonists, including injectable semaglutide for diabetes (Ozempic®), have prompted health systems to consider how access to these treatments should be prioritized and reimbursed. Little is known about how reimbursement restrictions on GLP-1 receptor agonists influence treatment patterns and glycemic control after treatment discontinuation. What this study adds: Following a national reimbursement restriction in Denmark, more than one in four patients discontinued injectable semaglutide for diabetes, and among those who switched treatment, SGLT2 inhibitors were the most common alternative, while most discontinuers did not initiate another glucose-lowering drug within six months. Approximately one in three discontinuers reinitiated their semaglutide therapy more than six months after stopping. Discontinuation of injectable semaglutide for diabetes was followed by a rise in HbA1c that, despite improvement over time, did not return to pre-discontinuation levels over 18 months, highlighting a potential clinical consequence of restricting access to an effective glucose-lowering treatment option.